Your browser doesn't support javascript.
loading
KRAS silencing alters chromatin physical organization and transcriptional activity in colorectal cancer cells.
Martins, Flávia; Machado, Ana Luísa; Ribeiro, Andreia; Oliveira, Susana Mendonça; Carvalho, Joana; Matthiesen, Rune; Backman, Vadim; Velho, Sérgia.
Afiliación
  • Martins F; i3S - Institute for Research and Innovation in Health.
  • Machado AL; i3S - Institute for Research and Innovation in Health.
  • Ribeiro A; i3S - Institute for Research and Innovation in Health.
  • Oliveira SM; i3S - Institute for Research and Innovation in Health.
  • Carvalho J; i3S - Institute for Research and Innovation in Health.
  • Matthiesen R; Universidade Nova de Lisboa.
  • Backman V; Northwestern University.
  • Velho S; i3S - Institute for Research and Innovation in Health.
Res Sq ; 2024 Apr 16.
Article en En | MEDLINE | ID: mdl-38410476
ABSTRACT
Clinical data revealed that KRAS mutant tumors, while initially sensitive to treatment, rapidly bypass KRAS dependence to acquire a drug-tolerant phenotype. However, the mechanisms underlying the transition from a drug-sensitive to a drug-tolerant state still elude us. Here, we show that global chromatin reorganization is a recurrent and specific feature of KRAS-dependent cells that tolerated KRAS silencing. We show that KRAS-dependent cells undergo G0/G1 cell cycle arrest after KRAS silencing, presenting a transcriptomic signature of quiescence. Proteomic analysis showed upregulated chromatin-associated proteins and transcription-associated biological processes. Accordingly, these cells shifted euchromatin/heterochromatin states, gained topologically associating domains, and altered the nanoscale physical organization of chromatin, more precisely by downregulating chromatin packing domains, a feature associated with the induction of quiescence. In addition, they also accumulated transcriptional alterations over time leading to a diversification of biological processes, linking chromatin alterations to transcriptional performance. Overall, our observations pinpoint a novel molecular mechanism of tolerance to KRAS oncogenic loss driven not by specific gene alterations but by global reorganization of genomic information, in which cells transition chromatin domain structure towards a more quiescent state and gain transcriptional reprogramming capacity.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Res Sq Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Res Sq Año: 2024 Tipo del documento: Article